Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Poll: Most are satisfied with their health insurance, but a quarter report denials or delays - 2Sixteen Kenyans missing in Russia after army recruitment
- 3Eli Lilly weight-loss drug appears to suppress binge-eating signal, small study finds
- 4Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
- 5How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- Oldest evidence of human fire-making discovered at site in England
- How a Middle East War Becomes a Retail Price Hike
- Which sandwich do you find totally delectable? !
- Exploring the Market: Unsold Rams May Be Less expensive Than You Naturally suspect
- The 2026 'Super Bowl of Astronomy' starts today — here's what's happening
- Favored Vehicle for Seniors: Make Your Determination
- Manual for Picking Coastline Travel
- How Mars' ancient lakes grew shields of ice to stay warm as the Red Planet froze
